2. Antibody-drug Conjugate/ADC Related JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  3. Antibody-Drug Conjugates (ADCs) EGFR
  4. Trastuzumab deruxtecan (solution)

Trastuzumab deruxtecan (solution)  (Synonyms: DS-8201 (solution); DS-8201a (solution))

Cat. No.: HY-138298
SDS COA Handling Instructions

Molarity Calculator

Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.

For research use only. We do not sell to patients.

Trastuzumab deruxtecan (solution) Chemical Structure

Trastuzumab deruxtecan (solution) Chemical Structure

CAS No. : 1826843-81-5

Size Price Stock Quantity
Solvent
1 mg (10 mg/mL * 100 μL in Aqueous solution) USD 880 In-stock
Solvent
5 mg (10 mg/mL * 500 μL in Aqueous solution) USD 2000 In-stock
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of Trastuzumab deruxtecan (solution):

Trastuzumab deruxtecan (solution) Related Antibodies

Top Publications Citing Use of Products

View All EGFR Isoform Specific Products:

View All Isoforms
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer[1][2].

In Vitro

Trastuzumab deruxtecan (1 pM-10 nM; 5 days) (solution) inhibits the growth of HER2-positive KPL-4 cells, with an IC50 of 109.7 pM[2].
Trastuzumab deruxtecan (10 nM; 5 days) (solution) shows bystander killing effects in HER2-negative MDA-MB-468 cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Trastuzumab deruxtecan (solution) Related Antibodies

Cell Viability Assay[2]

Cell Line: KPL-4 and MDA-MB-468 cells
Concentration: 1, 10, 100, 1000, 10000 pM
Incubation Time: 5 days
Result: Killed HER2-positive KPL-4 cells only.
In Vivo

Trastuzumab deruxtecan (3 mg/kg; a single i.v.) (solution) shows antitumor activity against not only HER2-positive tumors but also HER2-negative tumors under the co-inoculated condition[2].
Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) (solution) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female BALB/c nude mice injected with NCI-N87 and MDA-MB-468-Luc cells[2]
Dosage: 3 mg/kg
Administration: A single i.v.
Result: Almost all of the HER2-positive and HER-negative cells disappeared and there were little or no cancer cells remaining in the tumors.
Clinical Trial
Molecular Weight

153000 (average)

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Trastuzumab deruxtecan]
Shipping

Shipping with dry ice.
Storage

-80°C, protect from light
Purity & Documentation

Purity: 99.40%

SDS (251 KB)

COA (231 KB) Others (109 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Trastuzumab deruxtecan (solution) Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Trastuzumab deruxtecan (solution)1826843-81-5DS-8201 (solution) DS-8201a (solution)Antibody-Drug Conjugates (ADCs)EGFRAntibody-Drug ConjugatesEpidermal growth factor receptorErbB-1HER1humanepidermalgrowthfactorHER2antibody-drugconjugateADCantitumorcancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Trastuzumab deruxtecan (solution)
Cat. No.:
HY-138298
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.